Natureza® conducts research focused on the development of novel antimicrobial formulation strategies intended to address persistent challenges associated with resistant organisms. The Company has evaluated multiple antimicrobial candidates designed to support new approaches to microbial control in settings where conventional treatments face limitations.

Two formulation platforms have demonstrated in-vitro antimicrobial activity against organisms associated with high levels of treatment resistance. These systems are being evaluated for non-systemic applications, including topical and surface-based use, where formulation performance, stability, and safety can be assessed without reliance on traditional drug development pathways.

One formulation has demonstrated activity against Candida auris and has been evaluated in topical and surface-based formats. Laboratory testing has shown stable antimicrobial performance under controlled conditions, supporting further investigation for healthcare and environmental applications.

A second formulation has demonstrated activity against Pseudomonas species, including biofilm-forming organisms. This work has included evaluation of formulation behavior in delivery formats designed for localized exposure. Laboratory studies have also identified anti-inflammatory properties in controlled experimental models.

Natureza is actively exploring opportunities to license its patented formulations for research, development, and collaborative evaluation.

Intellectual Property

Natureza’s findings contribute to evolving approaches in antimicrobial development by addressing long-standing challenges associated with resistance pressure and development cost. By focusing on formulation-based antimicrobial strategies rather than traditional systemic drug discovery, this approach supports a more sustainable path for advancing antimicrobial technologies.